Organon & Co. (NYSE:OGN) Shares Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lifted its stake in shares of Organon & Co. (NYSE:OGN) by 43.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,157 shares of the company’s stock after buying an additional 6,096 shares during the period. Crossmark Global Holdings Inc.’s holdings in Organon & Co. were worth $385,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Versant Capital Management Inc lifted its position in Organon & Co. by 200.2% during the 2nd quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock worth $25,000 after acquiring an additional 805 shares during the period. William B. Walkup & Associates Inc. purchased a new position in shares of Organon & Co. in the second quarter worth about $31,000. Atlas Capital Advisors LLC lifted its holdings in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after purchasing an additional 2,147 shares during the period. Abich Financial Wealth Management LLC boosted its position in Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after buying an additional 2,315 shares during the last quarter. Finally, Rothschild Investment LLC acquired a new position in Organon & Co. in the 2nd quarter worth approximately $54,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Trading Down 1.8 %

Organon & Co. stock opened at $15.03 on Monday. The firm has a market cap of $3.87 billion, a PE ratio of 2.98, a P/E/G ratio of 0.70 and a beta of 0.84. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $23.10. The stock’s 50 day simple moving average is $18.14 and its two-hundred day simple moving average is $19.95. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $0.78 earnings per share. Analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be issued a $0.28 dividend. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.45%. Organon & Co.’s payout ratio is 22.22%.

Analyst Ratings Changes

Several analysts have recently commented on OGN shares. JPMorgan Chase & Co. downgraded shares of Organon & Co. from a “neutral” rating to an “underweight” rating and upped their price objective for the company from $18.00 to $20.00 in a report on Friday, September 6th. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.